News

$25m for genome editing start-up
Enlarge image

FinancingSwitzerlandUKSwedenGermany

$25m for genome editing start-up

25.04.2014 - Crispr Therapeutics has raised $25m in a series A investment. With the money, the newly formed Swiss biopharma company plans on translating its gene editing technology into medicines for genetic diseases.

The CRISPR/Cas9 system can be programmed with RNA to cut DNA within the genome, allowing the deletion, insertion or correction of individual genes. With the help of these enzymes, scientists and clinicians can adapt specific target genes, to tackle both recessive and dominant genetic diseases. Crispr Therapeutics, a Swiss start-up specialising in the CRISPR technology, now aims to use the platform for the development of medicines for human diseases, after securing the rights to the foundational intellectual property covering the use of CRISPR/Cas9 genome editing in human therapeutics. US investor Versant Ventures is financing the endeavor with $25m. Tom Woiwode, venture partner of Versant Ventures, explained: “We believe that Crispr Therapeutics has immense potential, as it is uniquely positioned to translate this technology into human therapeutics, thanks to its foundational intellectual property and its multi-disciplinary team of experts, including senior industry executives, world-renowned academics, and clinicians.”

The company also announced their founding team comprising interdisciplinary scientists specialised on CRISPR/Cas9, genome editing, stem cell biology, advanced drug delivery technologies, RNA interference and gene silencing. The team includes renowned scientists from the Massachusetts Institute of Technology and Harvard University, among others. One of the members and co-inventor of the CRISPR/Cas9 technology, Emmanuelle Charpentier, a professor at the Helmholtz Centre for Infection Research and Hannover Medical School, Germany and the Laboratory for Molecular Infection Medicine at Umeå University, Sweden, commented: “CRISPR/Cas9 has truly democratised genome editing, with many areas of research being transformed due to the technology’s ease of use and broad applicability. The collective efforts of the broader academic research community are in turn driving tremendous progress in the field.”

© eurobiotechnews.eu/um

BusinessSwitzerlandUK

23.04.2014 In an effort to focus on key businesses, pharma giant Novartis is joining forces with long-time rival GlaxoSmithKline in a multi-billion Euro asset exchange and an OTC joint venture.

FinanceSwedenFrance

18.04.2014 Oxthera AB, a Swedish biopharma company with a focus on rare diseases, has gained a SEK70m cash injection to continue its clinical programme for primary hyperoxaluria.

FundingEU

17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.

BusinessGermanyFrance

15.04.2014 German flavour and scent specialist Symrise has announced its plans to acquire French pet-food ingredients maker Diana Group for €1.3bn.

BioeconomySpain

14.04.2014 Spanish Neol Biosolutions and the Center for Second Generation Biofuels are starting a partnership to scale-up Neol's waste-to-oil technology.

EvidenceUKSwitzerland

11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.

BusinessSwitzerlandSpain

09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.

Status ReportSwitzerland

08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.

NanobiotechnologyItaly

07.04.2014 Scientists from the University of Udine have designed, produced and tested a prototype for a "DNA origami" nanorobot that can potentially deliver biological activators in-vivo.

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/news/pos/2.html

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • RENEURON (UK)3.60 GBP13.6%
  • EPIGENOMICS (D)5.74 EUR10.4%
  • PROTHENA PLC (IE)36.95 USD9.5%

FLOP

  • CYTOS (CH)0.13 CHF-18.8%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • THERAMETRICS (CH)0.10 CHF-9.1%

TOP

  • BIOTECH PHARMACON (N)19.00 NOK67.4%
  • WILEX (D)0.82 EUR39.0%
  • E-THERAPEUTICS (UK)28.00 GBP34.9%

FLOP

  • CYTOS (CH)0.13 CHF-95.2%
  • BIONOR PHARMA (N)2.18 NOK-45.5%
  • DIAGENIC (N)0.78 NOK-38.1%

TOP

  • SILENCE THERAPEUTICS (UK)255.00 GBP6275.0%
  • IXICO (UK)67.00 GBP740.7%
  • PLETHORA (UK)10.62 GBP658.6%

FLOP

  • CYTOS (CH)0.13 CHF-96.8%
  • EVOCUTIS (UK)0.22 GBP-91.9%
  • ADDEX (CH)1.95 CHF-71.1%

No liability assumed, Date: 24.04.2014